Cyanotech (CYAN) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
23 Nov, 2025Executive summary
Net sales for Q1 FY2026 were $5.82M, down 1.3% year-over-year, with gross margin improving to 30.5% from 25.0% due to operational discipline and efficiency.
Net loss narrowed to $926K ($0.13 per diluted share) from $1.2M ($0.17 per share) year-over-year, reflecting improved cost controls.
Operating loss reduced to $753K from $1.04M, with operating expenses remaining flat.
Management remains focused on brand value, e-commerce, bulk ingredient markets, and sustainable cash flows amid macroeconomic challenges.
Trailing twelve months net sales were $24.1M, gross profit $7.2M (29.7% margin), and net loss $2.93M.
Financial highlights
Q1 FY2026 net sales: $5.82M, down from $5.90M in Q1 FY2025; gross profit: $1.77M (30.5% margin) vs. $1.48M (25.0% margin) year-over-year.
Operating loss improved to $753K from $1.04M; net loss for the quarter was $926K ($0.13/share), down from $1.2M ($0.17/share) year-over-year.
Cash at quarter-end was $383K; negative working capital deficit of $255K.
Trailing twelve months net sales: $24.14M, up from $23.82M; net loss $2.93M vs. $5.10M prior period.
Gross margin: 30.5% (Q1 FY2026) vs. 25.0% (Q1 FY2025); net loss per share: $(0.13) vs. $(0.17) year-over-year.
Outlook and guidance
Focus remains on stabilizing production, optimizing market channels, and leveraging core competencies.
Emphasis on higher-margin consumer products, bulk sales opportunities, and sustainable cash flows.
Management expects gross margin may face pressure from lower production volumes and increased competition.
Cost controls, production alignment with demand, and eCommerce initiatives are ongoing priorities.
No formal quantitative guidance provided; significant sales variability and macroeconomic risks noted.
Latest events from Cyanotech
- Flat sales, lower margins, and new product launches amid cost pressures and secured financing.CYAN
Q4 20243 Feb 2026 - Net sales up 15% to $5.9M, but gross margin and liquidity pressures persist.CYAN
Q1 20252 Feb 2026 - Annual meeting to elect directors, approve equity plan, and ratify auditor, with governance focus.CYAN
Proxy Filing2 Dec 2025 - Key votes include director elections, a new equity plan, and auditor ratification for 2024.CYAN
Proxy Filing2 Dec 2025 - Director elections, auditor ratification, and triennial say-on-pay vote headline the agenda.CYAN
Proxy Filing2 Dec 2025 - Q2 sales up 19.3%, gross margin at 34.3%, operating income positive, but liquidity risks remain.CYAN
Q2 202618 Nov 2025 - Revenue up 5% and losses narrowed, but going concern risk remains due to liquidity and debt issues.CYAN
Q4 202520 Jun 2025 - Q2 FY2025 saw lower sales, margin compression, and ongoing liquidity challenges.CYAN
Q2 202513 Jun 2025 - Q3 sales rose 10.6% YoY, but ongoing losses and liquidity risks raise going concern doubts.CYAN
Q3 20255 Jun 2025